ES2180633T3 - Uso de derivados de pteridina como inhibidores de la no-sintasa. - Google Patents

Uso de derivados de pteridina como inhibidores de la no-sintasa.

Info

Publication number
ES2180633T3
ES2180633T3 ES95919422T ES95919422T ES2180633T3 ES 2180633 T3 ES2180633 T3 ES 2180633T3 ES 95919422 T ES95919422 T ES 95919422T ES 95919422 T ES95919422 T ES 95919422T ES 2180633 T3 ES2180633 T3 ES 2180633T3
Authority
ES
Spain
Prior art keywords
pct
inhibitors
pteridine derivatives
synthease
sec
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES95919422T
Other languages
English (en)
Inventor
Wolfgang Pfleiderer
Harald Schmidt
Rainer Henning
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Verinos Operations GmbH
Original Assignee
Vasopharm Biotech GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vasopharm Biotech GmbH filed Critical Vasopharm Biotech GmbH
Application granted granted Critical
Publication of ES2180633T3 publication Critical patent/ES2180633T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/99—Enzyme inactivation by chemical treatment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D475/00—Heterocyclic compounds containing pteridine ring systems
    • C07D475/02—Heterocyclic compounds containing pteridine ring systems with an oxygen atom directly attached in position 4
    • C07D475/04—Heterocyclic compounds containing pteridine ring systems with an oxygen atom directly attached in position 4 with a nitrogen atom directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D475/00—Heterocyclic compounds containing pteridine ring systems
    • C07D475/06—Heterocyclic compounds containing pteridine ring systems with a nitrogen atom directly attached in position 4
    • C07D475/08—Heterocyclic compounds containing pteridine ring systems with a nitrogen atom directly attached in position 4 with a nitrogen atom directly attached in position 2

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurosurgery (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Communicable Diseases (AREA)
  • Reproductive Health (AREA)
  • Virology (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)

Abstract

LA PRESENTE INVENCION TRATA DE LA UTILIZACION DE DERIVADOS DE LA PTERIDINA DE FORMULA GENERAL (I), EN LA QUE X ES O, NH O NALCANOILO DE C{SUB,1}-C{SUB,5}, R{SUP,3} ES EL RADICAL OR{SUP,4}, NR{SUP,5}R{SUP,6} O -S(O){SUB,M}R{SUP,7} Y R, R{SUP,1}, R{SUP,2}, R{SUP,4}, R{SUP,6}, R{SUP,7} Y M TIENEN LOS SIGNIFICADOS DADOS EN LA REIVINDICACION 1; SON INHIBIDORES DE LA SINTETASA DEL MONOXIDO DE NITROGENO; PARA EL TRATAMIENTO DE ENFERMEDADES, QUE SON CAUSADAS POR UN ELEVADO NIVEL DE MONOXIDO DE NITROGENO.
ES95919422T 1994-05-24 1995-05-06 Uso de derivados de pteridina como inhibidores de la no-sintasa. Expired - Lifetime ES2180633T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE4418096A DE4418096A1 (de) 1994-05-24 1994-05-24 Verwendung von Pteridin-Derivaten als Hemmstoffe der NO-Synthase

Publications (1)

Publication Number Publication Date
ES2180633T3 true ES2180633T3 (es) 2003-02-16

Family

ID=6518841

Family Applications (1)

Application Number Title Priority Date Filing Date
ES95919422T Expired - Lifetime ES2180633T3 (es) 1994-05-24 1995-05-06 Uso de derivados de pteridina como inhibidores de la no-sintasa.

Country Status (9)

Country Link
US (1) US5902810A (es)
EP (1) EP0760664B1 (es)
JP (1) JP4138870B2 (es)
AT (1) ATE223220T1 (es)
CA (1) CA2189131C (es)
DE (2) DE4418096A1 (es)
ES (1) ES2180633T3 (es)
PT (1) PT760664E (es)
WO (1) WO1995031987A1 (es)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1077886C (zh) 1993-10-21 2002-01-16 G·D·瑟尔公司 用作一氧化一氮合酶抑制剂的脒基衍生物
ES2206571T3 (es) * 1995-04-20 2004-05-16 G.D. SEARLE & CO. Agentes de amidino ciclico utiles como inhibidores de la oxido nitrico sintasa.
US5945408A (en) * 1996-03-06 1999-08-31 G.D. Searle & Co. Hydroxyanidino derivatives useful as nitric oxide synthase inhibitors
IL123884A (en) * 1996-07-31 2002-04-21 Cmic Co Ltd 6-formylpterin derivatives and oligomers and polymers thereof, for use as active oxygen scavengers
US5922713A (en) * 1997-06-26 1999-07-13 Werner; Ernst Inhibition of nitric oxide synthase
US5981556A (en) * 1997-07-22 1999-11-09 G.D. Searle & Co. 1,3-diazolino and 1,3-diazolidino heterocycles as useful nitric oxide synthase inhibitors
DE59703603D1 (de) * 1997-10-06 2001-06-28 Ernst Werner Pteridinderivate als NO Synthase-Hemmer
EP1085846A2 (en) * 1998-06-08 2001-03-28 Advanced Medicine, Inc. Multibinding inhibitors of microsomal triglyceride transferase protein
JP2002517502A (ja) 1998-06-10 2002-06-18 ジー・ディー・サール・アンド・カンパニー 複素二環状及び三環状一酸化窒素シンターゼ阻害剤
DE69920757T2 (de) * 1998-12-28 2005-12-15 4 AZA Bioscience N.V. Immunosuppressive wirkungen von pteridinderivaten
US7276506B2 (en) 1998-12-28 2007-10-02 4 Aza Bioscience Nv Immunosuppressive effects of pteridine derivatives
DE19944767A1 (de) * 1999-09-17 2001-03-29 Vasopharm Biotech Gmbh & Co Kg N-substituierte 4-Aminopteridine, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
US6344473B1 (en) 2000-08-07 2002-02-05 G.D. Searle & Co. Imidazoles useful as nitric oxide synthase inhibitors
WO2002076954A1 (en) * 2001-03-23 2002-10-03 Smithkline Beecham Corporation Compounds useful as kinase inhibitors for the treatment of hyperproliferative diseases
CA2500952C (en) * 2002-10-04 2011-04-26 Prana Biotechnology Limited Neurologically-active compounds
WO2005037286A1 (en) * 2003-03-25 2005-04-28 Vasopharm Biotech Gmbh Use of pteridine derivatives for the treatment of increased intracranial pressure and secondary ischemia
GB2405793A (en) * 2003-09-12 2005-03-16 4 Aza Bioscience Nv Pteridine derivatives for treating TNF-alpha related disorders
PL1708690T3 (pl) 2003-11-17 2017-01-31 Biomarin Pharmaceutical Inc. Leczenie fenyloketonurii za pomocą BH4
WO2006055511A2 (en) 2004-11-17 2006-05-26 Biomarin Pharmaceutical Inc. Stable tablet formulation of tetrahydrobiopterin
US20100144693A1 (en) 2006-04-14 2010-06-10 Prana Biotechnology Limited Method of treatment of age-related macular degeneration (amd)
US10144736B2 (en) 2006-07-20 2018-12-04 Gilead Sciences, Inc. Substituted pteridines useful for the treatment and prevention of viral infections
US9259426B2 (en) 2006-07-20 2016-02-16 Gilead Sciences, Inc. 4,6-di- and 2,4,6-trisubstituted quinazoline derivatives useful for treating viral infections
PT2299810T (pt) 2008-06-05 2020-03-04 Bausch Health Ireland Ltd Formulações tópicas farmacológicas que contêm uma baixa concentração de peróxido de benzoilo em suspensão em água e um solvente orgânico miscível em água
US9216178B2 (en) 2011-11-02 2015-12-22 Biomarin Pharmaceutical Inc. Dry blend formulation of tetrahydrobiopterin
PL3097102T3 (pl) 2015-03-04 2018-04-30 Gilead Sciences Inc Związki 4,6-diamino-pirydo[3,2-d]pirymidyny modulujące działanie receptora toll-podobnego
KR102268448B1 (ko) 2016-09-02 2021-06-22 길리애드 사이언시즈, 인코포레이티드 톨 유사 수용체 조정제 화합물
ES2826748T3 (es) 2016-09-02 2021-05-19 Gilead Sciences Inc Derivados de 4,6-diamino-pirido[3,2-d]pirimidina como moduladores de receptores de tipo Toll
TW202210480A (zh) 2019-04-17 2022-03-16 美商基利科學股份有限公司 類鐸受體調節劑之固體形式
TWI751517B (zh) 2019-04-17 2022-01-01 美商基利科學股份有限公司 類鐸受體調節劑之固體形式
TWI879779B (zh) 2019-06-28 2025-04-11 美商基利科學股份有限公司 類鐸受體調節劑化合物的製備方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4079056A (en) * 1975-03-31 1978-03-14 The United States Of America As Represented By The Department Of Health, Education And Welfare Method of making pteridine compounds
DE3378634D1 (en) * 1982-09-20 1989-01-12 Wellcome Found Pharmaceutically active pteridine derivatives
GR850294B (es) * 1984-02-03 1985-06-05 Res Corp Technologies Inc
IT1204612B (it) * 1987-05-14 1989-03-10 Bioresearch Spa Pteridine atte alla preparazione di composizioni farmaceutiche ad attivita' antiamnesica
JP2534423B2 (ja) * 1991-12-26 1996-09-18 コーネル・リサーチ・ファンデーション・インコーポレイテッド 酸化窒素の過剰生産から生じる血管失調を阻止する阻害剤
JPH0656669A (ja) * 1992-06-11 1994-03-01 Asahi Breweries Ltd 活性酸素消去作用を持つプテリン誘導体製剤
JPH08504798A (ja) * 1992-12-18 1996-05-21 ザ ウエルカム ファウンデーション リミテッド 酵素阻害薬としての，ピリミジン，ピリジン，プテリジノンおよびインダゾール誘導体
JPH0834782A (ja) * 1994-05-20 1996-02-06 Nissan Chem Ind Ltd イミノ型スルホニルウレア及び除草剤

Also Published As

Publication number Publication date
JP4138870B2 (ja) 2008-08-27
JPH10504023A (ja) 1998-04-14
US5902810A (en) 1999-05-11
PT760664E (pt) 2003-01-31
ATE223220T1 (de) 2002-09-15
WO1995031987A1 (de) 1995-11-30
DE59510362D1 (de) 2002-10-10
CA2189131C (en) 2007-03-06
EP0760664B1 (de) 2002-09-04
DE4418096A1 (de) 1995-11-30
CA2189131A1 (en) 1995-11-30
EP0760664A1 (de) 1997-03-12

Similar Documents

Publication Publication Date Title
ES2180633T3 (es) Uso de derivados de pteridina como inhibidores de la no-sintasa.
TR199901259T2 (xx) Nos inhibit�rleri olarak fayda ta��yan 6-fenilpiridil-2-amin t�revleri
ES2173185T3 (es) Empleo de derivados de tetrahidropteridina como inhibidores de la no-sintasa.
ATE228507T1 (de) Substituierte 6-phenylphenanthridine
ATE264846T1 (de) Substituierte benzimidazol-derivaten und ihre verwendung zur behandlung retroviraler infektionen
MX9700557A (es) Dihidrobenzofuranos.
TR200000535T2 (tr) NOS önleyicileri olarak ekli halka ikameleri içeren 2-aminopiridinler.
TR200201205T2 (tr) N-ikame edilmiş karbamoiloksialkil-azolyum türevleri.
PA8432901A1 (es) Compuestos de piridilpirrol
FI964772A0 (fi) (a)-annelloidut pyrrolijohdannaiset ja niiden käyttö farmasiassa
ATE326466T1 (de) Imidazopyridinderivate zur verwendung bei der behandlung von herpes-vireninfektion
DE69924292D1 (de) Pyrazol verbindungen und ihre verwendung
FR2712591B1 (fr) Nouvelles arylpipérazines dérivées d'indole, leur préparation et leur utilisation thérapeutique.
TR200102524T2 (tr) Dihetero sübstitüe edilmiş metaloproteaz inhibitörleri.
TR200001010T2 (tr) Ürokinaz önleyicileri olan izokinolinler.
DK0920426T3 (da) Hidtil ukendte thiazolderivater med phosphodiesteraseinhiberende virkning
ATE181731T1 (de) Isothioharnstoff-derivate als no synthase hemmer
TR200000907T2 (tr) Nötrofil elastaz inhibitörleri olarak pirolopirolon türevleri.
TR199800813T2 (xx) Nitrik oksit sintaz�n�n �nleyicileri olarak amidin, isot�re t�revleri.
ATE187461T1 (de) Cyklopeptolide
DK47688D0 (da) 5-(3-alkyl-5-tert.butyl-4-hydroxyphenyl)-2-amino-6h-1,3,4-thiadiaziner, deres fremstilling og anvendelse som laegemiddel
SE9603285D0 (sv) New compounds
LV10951A (lv) 4-Hinolinilatvasinajumi
ATE204878T1 (de) Therapeutische verbindungen
DK1104419T3 (da) N-substituerede azabicyloheptan-derivater, deres fremstilling og anvendelse